FEATURED CONTENT
2024 Incentive Compensation Benchmarking Studies
The field force is the most critical customer engagement channel for pharmaceutical companies. However, to perform at their best, they need the right motivation. That’s where a well-designed incentive compensation (IC) plan becomes critical. It acts as a strategic lever to align efforts with business impact. Axtria’s 2024 IC Benchmarking Studies (US and Global) provide IC leaders with valuable insights and best practices to build IC plans that inspire, empower, and deliver. Download now.
KNOWLEDGE STREAM
Harnessing the Power of Gen AI to Improve Patient Outcomes & Treatment Plans
In an interview with Fintech TV, Jassi Chadha, President and CEO of Axtria, discusses how generative AI is revolutionizing healthcare by improving patient outcomes and optimizing treatment plans. He explains how this technology helps pharma companies personalize care with advanced data analysis and predictive insights, paving the way for a smarter, more patient-focused future.
SPECIAL REPORT
Frost & Sullivan’s Pharmaceutical Commercialization Solutions and Services Industry Radar Report
Axtria was named the leader in Frost & Sullivan's inaugural Pharmaceutical Commercialization Solutions and Services Industry Radar Report. Companies were evaluated using two indices: Growth Index (GI) for performance and strategy execution and Innovation Index (II) for developing globally relevant, customer-focused solutions addressing disruptive megatrends. Get complimentary access to the full report here.
UPCOMING WEBINAR
Understanding Key Trends Transforming Pharma Commercial Model Design
Join us on Thursday, January 16, at 1:00 PM ET for our upcoming Axtria Ignite webinar, where we’ll discuss how pharmaceutical companies are approaching the emerging trends that are transforming the industry and how they are evolving their commercial model design to maximize performance.
LEADERS' PERSPECTIVES
Generative AI: Revolutionizing Diagnostics and Personalized Care
Generative AI is redefining what’s possible in healthcare. This article, written by Shikha Singhal, Principal of Data Science at Axtria, explores how MedTech companies are leveraging GenAI to improve diagnostic accuracy, detect diseases earlier, and deliver tailored treatments that optimize patient outcomes.
TIMELESS INSIGHTS
The Role of Integrated Evidence Planning in Biopharma Innovation
Integrated Evidence Planning (IEP) is essential for driving biopharma success by aligning evidence generation across the drug development process. This article demonstrates how Axtria’s IEP framework helped a small pharma client successfully launch a medical device, showcasing the value of real-world evidence, economic modeling, and effective evidence communication in shaping market access strategies.
NEWS CAPSULE
PMSA 2025 Global Summit
Axtria proudly announces its Gold Sponsorship at the upcoming PMSA 2025 Global Summit, which will be held from February 4 - 6, 2025 in Hyderabad, India. Join us for engaging discussions offering valuable insights from our subject matter experts.
Axtria at the New York Stock Exchange
A proud moment at the NYSE! Our CEO, Jaswinder Chadha, joined Judy Shaw on her show, NYSE Floor Talk, to discuss Axtria's journey of growth and innovation. With GenAI and advanced analytics, we’re enabling pharmaceutical companies to innovate faster, enhance therapy access, and achieve commercial success, all while improving patient outcomes.
